Also named director, Michigan Institute for Clinical & Health Research (MICHR) and principal investigator for U-Ms Clinical & Translational Science Award by the National Institutes of Health
The University of Michigan Board of Regents has approved the appointment of Thomas P. Shanley, M.D., as associate dean for clinical and translational research at the U-M Medical School, and director of the Michigan Institute for Clinical & Health Research. The National Institutes of Health also approved Shanley as principal investigator for U-M’s Clinical & Translational Science Award.
“Dr. Shanley is an ideal choice to lead MICHR and continue to pursue our vision for enabling and enhancing clinical and translational research at U-M,” said Ora Pescovitz, M.D., chief executive officer of the U-M Health System and executive vice president for medical affairs for U-M. “His vast experience and proven leadership at Michigan are highly valued, and we look forward to his contributions to enhancing our clinical research enterprise.”
Shanley replaces Kenneth J. Pienta, M.D., who previously held both positions before he stepped down in April of this year.
Shanley is the Janette Ferrantino Professor of Pediatrics. Before being appointed associate dean, he was the director of Pediatric Critical Care Medicine and the director of Clinical and Translational Research for the Medical School’s Department of Pediatrics and Communicable Diseases.
As a pediatric intensive care physician, his clinical interests include management of critically ill children, notably those afflicted with hypoxemic respiratory failure from severe lung diseases and severe sepsis and septic shock triggered by infections.
Shanley’s research roots are at the University of Michigan, where he trained in the early to mid-1990s. His research interests have spanned the translational spectrum from basic science investigation into the role of phosphatases in modulating inflammatory signal transduction pathways to translational research examining the genomics of pediatric sepsis. His laboratory is currently examining the effect of tight glucose control on the immune response in children undergoing oxidant stress related to cardiopulmonary bypass for heart surgery.
Shanley is the site principle investigator for the C.S. Mott Children’s Hospital Pediatric Intensive-Care Unit’s participation in the National Institute of Child Health & Human Development-sponsored Collaborative Pediatric Critical Care Research Network, which is studying a number of outcomes in critically ill children. He is also the site PI for a National Heart Lung and Blood Institute-sponsored clinical trial in sedation management for children needing prolonged mechanical ventilation. He has been involved in the mentoring of a number of post-doctoral trainees from a variety of clinical subspecialties and research departments.
On May 19, 2011, the U-M Regents also named Shanley as the associate vice president for for clinical and translational research of the U-M Health System.
The Michigan Institute for Clinical & Health Research provides 360º support for every phase of clinical & translational research – from consultation on an idea to help promoting results. MICHR educates, funds, connects, and supports research teams across the University of Michigan. MICHR’s team of more than 100 professional staff and 65 faculty moves medicine forward to improve health treatments and find cures. MICHR was created in 2006 and received a Clinical & Translational Science Award from the National Institutes of Health in 2007, making it part of a national consortium of 55 academic research institutions. For more information, visit www.michr.umich.edu.
About Clinical & Translational Research:
Clinical and translational research spans much of the research performed across the University of Michigan in areas related to human health.
Clinical research means biomedical or health-related studies conducted in humans (or on material of human origin), and includes both interventional and observational studies.
Translational research means research that applies discoveries generated in the laboratory to studies in humans (bench to bedside), or that speeds the adoption of best practices into community settings (bedside to practice).